BURLINGAME, Calif., Nov. 21, 2023 /PRNewswire/ — According to Coherent Market Insights, Global Sepsis Diagnostics Market size was valued at US$ 841.4 Million in 2023 and is expected to surpass US$ 1,624.6 Million by 2030 and is anticipated to witness a compound annual growth rate (CAGR) of 9.9% during the forecast period (2023-2030).
Key Trends and Analysis of the Global Energy Retrofit Market
The rising number of cases of infectious diseases such as pneumonia, cholera, toxic shock syndrome, salmonellosis, COVID-19, and others is expected to drive growth of the global sepsis diagnostics market over the forecast period. For instance, according to the World Health Organization fact sheet published in February 2021, around 1.3-4.0 million cases of cholera are reported every year worldwide. Moreover, according to a research study published by the NCBI (National Center for Biotechnology Information) in November 2020, the prevalence of toxic shock syndrome is estimated to be approximately 0.8 to 3.4 per 100,000 in the U.S.
Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/1166
Global Sepsis Diagnostics Market – Driver
Increasing product launch by market players
Increasing product launches by market players are also expected to fuel overall market growth. For instance, on June 23, 2020, Presymptom, a medtech healthcare company, announced that the company developed test to predict which COVID-19 patients will develop sepsis before symptoms appear, and has received initial funding to accelerate development to help diagnose and save the lives of seriously ill patients. Presymptom Health has received an initial US$2.2 million in seed funding from Ploughshare Innovations to accelerate the development of the test, which will transform clinicians’ ability to provide appropriate treatment, potentially saving lives.
Global Sepsis Diagnostics Market – Restraint
Lack of awareness regarding Sepsis Diagnostics
Lack of awareness regarding sepsis diagnostics is expected to hinder market growth over the forecast period. For instance, on October 25, 2021, an article published in The National Center for Biotechnology Information stated that, to improve clinical outcomes, sepsis must be quickly identified and specifically treated. There is currently no diagnostic technique that can quickly detect or rule out infection. The high rates of broad-spectrum antimicrobial therapy used globally are a result of the lack of a good diagnostic tool, which is also likely to cause underrecognition (and overtreatment) of non-infectious inflammatory conditions. Novel treatments are urgently needed because antibiotic resistance is becoming more prevalent. The utility of screening tools may be increased by combining machine learning models with biomarkers, gene markers, and EMR data, but further research is necessary. Sepsis management and diagnosis continue to depend on careful patient assessment and reliable clinical judgment. These essential components of patient care should be supplemented by novel procedures, not replaced by them.
Request for Customization @ https://www.coherentmarketinsights.com/insight/request-customization/1166
Global Sepsis Diagnostics Market – Opportunity
Increasing disease awareness initiatives
Increasing disease awareness initiatives by non-profit organizations is expected to drive growth of the market in the near future. For instance, on April 10, 2023, Cone Health, a not-for-profit health system serving North Carolina, U.S., aimed to boost organizational compliance with the Severe Sepsis and Septic Shock Management Bundle (SEP-1), a National Quality Forum measure adopted by the Centers for Medicare & Medicaid Services (CMS), and reduce sepsis-related mortality. Cone Health utilized PINC AI technology to improve its sepsis treatment process. The health system aimed to obtain high SEP-1 bundle compliance rates to meet its compliance goals.
Global Sepsis Diagnostics Market- Cross Sectional Analysis:
Among Product Type, the Blood Culture Media segment is dominant during the forecast period in the North America region due to the key players focusing on organic strategies such as the launch of new equipment, which is expected to drive segment growth over the forecast period. For instance, On November 3, 2022, Immunexpress, Pty Ltd., a California, U.s. based molecular diagnostic company, announced the presentation of an abstract at the Association for Molecular Pathology 2022 Annual Meeting in Phoenix. The abstract is entitled “Multi-site validation of EDTA blood as a sample type for SeptiCyte Rapid CE-IVD, a near-patient diagnostic test for sepsis on the Biocartis Idylla System. The multi-site study was conducted at the University Hospital Bonn in Germany and the Hospital Foch in Suresnes, France. It investigated Immunexpress’ sepsis diagnostic tool, SeptiCyte Rapid CE-IVD, in 46 clinically confirmed sepsis and non-sepsis patients. A high degree of correlation (R2 = 0.95) was observed when comparing the SeptiScore values observed in these patients, processed either from undiluted EDTA blood collection tubes or from aPAXgene blood RNA tubes. The reproducibility of the EDTA blood result was further assessed by running a subset of the samples in triplicate.
Global Sepsis Diagnostics Market : Key Developments
On August 7, 2023, Immunexpress, a molecular diagnostic company focused on improving outcomes for patients suspected of sepsis, announced the adoption of SeptiCyte Rapid by FirstHealth of the Carolinas, a non-profit health system licensed for four hospitals in Pinehurst, Troy, Rockingham, and Raeford, North Carolina. SeptiCyte Rapid will be available at FirstHealth as a tool for differentiating sepsis-positive cases from patients with infection negative systemic inflammation.
Read complete market research report here at Sepsis Diagnostics Market, By Product Type, By Method, By Pathogen, By Technology, By End User, By Region (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)
Key Market Takeaways:
- The global sepsis diagnostics market is expected to exhibit a CAGR of 11.3% during the forecast period due to the increasing use of new technologies. For instance, on July 14, 2023, Asep Medical Holdings Inc., a Canada based biotechnology company, announced the results of a recent scientific study that concluded that severe COVID-19 is a form of sepsis based on analysis of blood gene expression signatures. Importantly, this study highlights the potential benefits of a rapid diagnostic test for sepsis, such as the Company’s SepsetER (TM) sepsis diagnostic test, that could identify COVID-19 patients at risk of developing severe sepsis as well as provide a path to a precision medicine approach to enable individualized treatment for the disease.
- Among Technology, immunoassays is expected to dominate the market over the forecast period and this is explained by the fact that a timely diagnosis of sepsis can result in effective treatment and a full recovery. On August 5, 2020, Beckman Coulter, a manufacturing company in biomedical testing, announced new analysis from the pivotal study of its novel monocyte distribution width (MDW) hematologic biomarker for sepsis detection. The analysis showed that abnormal MDW values, when considered along with the standard physiologic parameters at the time of patient presentation in the emergency department, signified a four-to six-fold higher probability of sepsis diagnosis. The pivotal study enrolled 2,158 emergency department patients in three academic centers and was the basis for U.S. FDA clearance of Beckman Coulter’s Early Sepsis Indicator.
- Key players operating in the Global Sepsis Diagnostics Market include BioMérieux SA, Thermo Fisher Scientific, Abbott Laboratories, Roche Diagnostics AG, Luminex Corporation, CytoSorbents Corporation, Becton Dickinson Company, Danaher Corporation, Axis-Shield Diagnostics, T2 Biosystems, EKF Diagnostics, Immunexpress Inc., Response Biomedical Corporation, and Bruker Corporation.
Global Sepsis Diagnostic Market Detailed Segmentation:
- By Product Type:
- Blood Culture Media
- Assays & Reagents
- Instruments
- Software
- By Method:
- Automated Diagnostics
- Conventional Diagnostics
- By Pathogen:
- Bacterial Sepsis
- Gram-Negative Bacterial Sepsis
- Gram-Positive Bacterial Sepsis
- Fungal Sepsis
- Others
- By Technology:
- Microbiology
- Molecular Diagnostics
- Immunoassays
- Flow Cytometry
- By End User:
- Hospitals
- Pathology & Reference Laboratories
- Research Laboratories & Academic Institutes
- By Region:
- North America
- By Country:
- U.S.
- Canada
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Country:
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Country/Region:
- South Africa
- Central Africa
- North Africa
Buy this Premium Research Report Now @ https://www.coherentmarketinsights.com/insight/buy-now/1166
Contact Us:
Mr. Shah
Senior Client Partner – Business Development
Coherent Market Insights
Phone:
US: +1-206-701-6702
UK: +44-020-8133-4027
Japan: +81-050-5539-1737
India: +91-848-285-0837
Email: [email protected]
Website: https://www.coherentmarketinsights.com
Follow Us: LinkedIn | Twitter
Logo: https://mma.prnewswire.com/media/902389/Coherent_Market_Insights_Logo.jpg
SOURCE Coherent Market Insights
